De Groot et al. previously showed that the IGF1R SNV G > T rs2016347 is associated with pathological response after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, emphasizing that genetic variation could impact treatment response in these patients [5]. This evidence concerns the gene ERBB2 and breast cancer.